| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000021277 |
| Receipt No. | R000024541 |
| Scientific Title | Surgical reconstruction using the hyper dry human amniotic membrane : recurrence pterygium (proliferative tissue is limited to a thing more than the limbus.) |
| Date of disclosure of the study information | 2016/03/01 |
| Last modified on | 2020/07/15 (Ver. 8) |
| Basic information | ||
| Public title | Surgical reconstruction using the hyper dry human amniotic membrane : recurrence pterygium (proliferative tissue is limited to a thing more than the limbus.) | |
| Acronym | Surgical reconstruction using the hyper dry human amniotic membrane | |
| Scientific Title | Surgical reconstruction using the hyper dry human amniotic membrane : recurrence pterygium (proliferative tissue is limited to a thing more than the limbus.) | |
| Scientific Title:Acronym | Surgical reconstruction using the hyper dry human amniotic membrane | |
| Region |
|
|
| Condition | ||
| Condition | recurrence pterygium | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Confirm non-recessive efficacy and safety |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Phase I,II |
| Assessment | |
| Primary outcomes | It is the presence or absence of recurrence until 52 weeks after a surgical operation |
| Key secondary outcomes | (1) Decimal visual acuity tests
(2) Ophthalmotonometry (3) An examination for slit lamp microscopy and anterior segment of eyeball OCT (4) Tensile speed of the pterygium tissue (measure it by anterior segment of eyeball OTC, and calculate it) (5) Funduscopy (6) A growth rate of the tissue |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | (1) After Benoxil ophthalmic solution dropping lotion in the eyes anesthesia, perform washing eyes, disinfection.
(2) After draping, put on ecarteur. (3) Add Xylocaine anesthesia to pterygium body by subconjunctival injection under a microscope(We use general anesthesia for the hope of patients). (4) Tear off corneal epithelium close against a front of the pterygium head. (5) Ablate pterygium tissue using a golf sword to the limbus from the head. (6) Ablate episcleral conjunctival epithelium and Tenon pouch enough and denude a sclera and excise pterygium. (7) Douche it in a raw diet of approximately 300 ml after insertion attachment under 3-5min conjunctiva with the microsponge which we soaked with 0.04% MMC enough. (8) The MMC becomes out of an accommodation to use it for a purpose to inhibit an activation (recurrence of the re-pterygium) of the subconjunctival proliferative tissue (9) Match the stromal aspect of the hyper dry human desiccation cowl (HD cowl) with a sclerotic exposed surface and trim the part of the resection side with ophthalmology cusp sword. (10) After put an HD cowl on the wounded surface, and arrival at sewing did an HD cowl to a sclera, repeat a conjunctiva stump on the top, and sew it up in a 1mm interior position; do. (11) Have top and bottom right and left move an eyeball and check follows and add suturation, if necessary( We confirm after consciousness returned in the case of a general anesthesia). (1) Is eye movement smooth? (2) Is there not the pull companion whom it is impossible for conjunctiva to do? (3) Does a suture not come off? (12) Steroid subconjunctival injection or eye drops etc. is provided because of resolution and picks up a contact lens for treatment when corneal epithelium of the pupillary area greatly suffers a loss. |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) age: The patients who relatively have good Patient 2) overall status of (at the agreement acquisition) 20 years old or older
3) The patients whom pathologic proliferative tissue invaded in recurrent pterygium across limbus. 4) The patients whom it is judged to be available for observation, the testing that conformed to a study enforcement plan and a survey |
|||
| Key exclusion criteria | 1) onset pterygium patient or pseudopterygium patients.
2)The patients whom a doctor judged safely for 2) study period if it was difficult hospital visiting and to come home. 3)The patients who complicate eye infection with 3) activity. 4)The patients who plan the enforcement of eye operations for evaluation eyes effective during 4) study period in (we assume the agreement acquisition study initiation). 5)one eyes are the patients of enucleation eyes or evisceration eyes. 6)For the group medicine of the planned drug (dropping lotion in the eyes anesthetic agent, fluorescein) to use during 6) study period, it is the patients with a history of the drug allergy. 7)The patients (saying that, however, the subjects who do not receive the study drug are possible) who participated in other studies or clinical studies within six months. 8)The patients whom a doctor judged as an object of this study in testing at pregnancy or 9 childbearing patients) agreement acquisition that we might be pregnant or hoped for pregnancy during study period or did not use appropriate contraception for if inadequate. |
|||
| Target sample size | 40 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | University of Toyama | ||||||
| Division name | Department of Ophthalmology | ||||||
| Zip code | 9300194 | ||||||
| Address | Sugitani 2630, Toyama City, Toyama Prefecture | ||||||
| TEL | 076-434-7363 | ||||||
| ahayashi@med.u-toyama.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | University of Toyama | ||||||
| Division name | Department of Ophthalmology | ||||||
| Zip code | 9300194 | ||||||
| Address | Sugitani 2630, Toyama City, Toyama Prefecture | ||||||
| TEL | +81-76-434-7363 | ||||||
| Homepage URL | |||||||
| ahayashi@med.u-toyama.ac.jp | |||||||
| Sponsor | |
| Institute | Toyama University Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Toyama University Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Takaoka city hospital, Nagasaki University Hospital, Toho University Omori Medical Center, Matsue Red Cross Hospital, Kochi Medical School Hospital, University of Occupational and Environmental Health, Yamagata University Hospital, Akita University Hospital, University of Fukui Hospital, The University of Tokyo Hospital, Oita University Hospital, Hiroshima University Hospital, Shimane University Hospital |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Ethics Committee, University of Toyama |
| Address | Sugitani 2630, Toyama City, Toyama Prefecture |
| Tel | 076-434-2281 |
| rinri@adm.u-toyama.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 富山大学附属病院(富山県)、長崎大学病院(長崎県)、東邦大学医療センター大森病院(東京都)、秋田大学医学部付属病院(秋田県)、松江赤十字病院(島根県)、高知大学医学部附属病院(高知県)、山形大学医学部附属病院(山形県)、福井大学医学部附属病院(福井県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000024541 |